Will SGK public coverage with Allianz Sigorta, Anadolu Sigorta, and Acibadem Sigorta employer plans cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Rezurock is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by TITCK?

The TITCK named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; TITCK review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Turkish-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Turkish Medical Association (TTB) and the Ministry of Health licensing directorate verifies the active license; the TITCK application records both the prescribing physician and the dispensing facility.

Can I receive Rezurock at home?

The dispensing facility must be Turkish-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 18,000 to 23,000 per month. Delivered quote within 24h.Get my quote

Rezurock access in Turkey: the TITCK named-patient pathway

How patients in the Republic of Turkiye legally obtain Rezurock (belumosudil) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Turkey access Rezurock (belumosudil) for chronic graft-versus-host disease (cGVHD) in adult and pediatric patients aged 12 years and older after failure of at least two prior lines of systemic therapy through the TITCK named-patient pathway, a the Turkish Medicines and Medical Devices Agency (Turkiye Ilac ve Tibbi Cihaz Kurumu)-administered mechanism that allows a Turkish-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in TRY.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Rezurock reaches patients in Turkey

Rezurock (belumosudil, an oral selective ROCK2 inhibitor, FDA-approved July 2021 for chronic graft-versus-host disease in adult and paediatric patients 12 years and older after failure of at least two prior lines of systemic therapy; marketed by Sanofi after the Kadmon acquisition) is not currently visible on the TITCK registered-product list at titck.gov.tr/dinamikmodul/43 as of 2026-05-31. Turkish patients access Rezurock through the Yurt Dışından İlaç Temini named-patient programme under Additional Article 7 of Law No. 1262 and TITCK Kılavuzu Revision 14 at portal.aifd.org.tr TITCK Kılavuzu Rev. 14. The treating haematologist files to the TITCK Commission for Evaluation of Medicines in Personal Treatment. The Rezurock-specific clinical justification must document: cGVHD diagnosis with organ-specific NIH consensus criteria; allogeneic stem cell transplant history; failure of at least two prior systemic therapy lines per the FDA label, which in Turkish practice typically includes corticosteroids plus ruxolitinib (Jakavi, on the SGK formulary for steroid-refractory cGVHD) plus at least one additional agent (ibrutinib, extracorporeal photopheresis, calcineurin inhibitors, mycophenolate mofetil); the intended dose of 200 mg once daily; and CYP3A4-interaction documentation (dose adjustments with strong inducers or PPI). The prescribing BMT centre's accreditation is required.

Where Rezurock is dispensed in Turkey

Rezurock is an oral chronic therapy administered in the post-allogeneic-BMT outpatient setting with NIH-consensus organ-specific cGVHD surveillance. Turkish tertiary BMT and haematology nodes include Hacettepe University Faculty of Medicine Department of Haematology and BMT Unit in Ankara at hastane.hacettepe.edu.tr; Ankara University İbni Sina Hospital and Cebeci Hospital Department of Haematology and BMT Unit; Istanbul University Çapa Faculty of Medicine Department of Haematology and BMT Unit; Marmara University Pendik Training and Research Hospital Department of Haematology and BMT; Ege University Faculty of Medicine Department of Haematology and BMT Unit in Izmir; Acıbadem Hospitals (Maslak, Altunizade, Atakent) Department of Haematology and BMT (private tertiary with international BMT case load) at acibademinternational.com; Anadolu Medical Center (Anadolu Sağlık Merkezi, affiliated with Johns Hopkins) Department of Haematology and BMT in Kocaeli; Memorial Şişli Hospital BMT; Medipol Mega University Hospital BMT; and LIV Hospital BMT in Istanbul. Hacettepe, Ankara University, and Acıbadem run the country's largest allogeneic-BMT case loads with structured cGVHD clinics. Paediatric Rezurock candidates (12 years and older) typically transition through Hacettepe İhsan Doğramacı Children's Hospital paediatric BMT into adult haematology.

What Rezurock costs in Turkey

The US reference WAC for Rezurock is approximately USD 20,000 to USD 22,000 per 30-day supply at the labelled dose of 200 mg once daily per Sanofi disclosures and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Annual US WAC at maintenance runs USD 240,000 to USD 260,000. Under the SGK Yurt Dışından İlaç Temini reimbursement framework, named-patient reimbursement is at the foreign-sourced price exempt from international reference pricing. No public TRY benchmark for Rezurock is observed on TITCK or SGK pages as of 2026-05-31. Do not estimate. Price snapshot: 2026-05-31. The TRY/USD spot rate from the Central Bank of Türkiye on the date of any quote should be footnoted. Ruxolitinib (Jakavi, the SGK-formulary alternative for steroid-refractory cGVHD) is on the SGK formulary at a substantially lower TRY price; the Rezurock SGK adjudication is conditional on documented inadequate response to or intolerance of ruxolitinib plus the corticosteroid baseline. Cost layers for SGK-insured patients: drug cost mostly absorbed by SGK upon Commission approval; co-payments and administrative fees; the dispensing TEB or USHAŞ logistics; and Reserve Meds concierge fee where US-sourced product or expedited timing is preferred.

Funding and access barriers for Rezurock in Turkey

cGVHD affects approximately 30 to 60% of allogeneic stem-cell transplant recipients; the Turkish BMT case load at Hacettepe, Ankara University, Acıbadem, and Anadolu Medical Center provides the clinical context. Public funding: SGK reimbursement under Yurt Dışından İlaç Temini is the dominant funding pathway for confirmed two-line-failure cGVHD cases. SGK adjudication requires documented failure of corticosteroids plus ruxolitinib (Jakavi, locally registered and SGK-listed for steroid-refractory cGVHD) plus at least one additional systemic agent. For SGK-insured patients (the vast majority), full reimbursement is generally available for approved Şahsi tedavi Rezurock cases. The dispensing channel is TEB or USHAŞ, not the local eczane. Private health insurers (Acıbadem Sigorta, Anadolu Sigorta, AXA Sigorta, Allianz Sigorta, Mapfre Sigorta, Generali, Türk Nippon Sigorta) are supplementary for the small population without SGK coverage; coverage of unregistered haematology imports is policy-specific. Sanofi Turkey patient-support programmes operate case-by-case for cGVHD patients. The İTS drug-tracking-system requirement adds a track-and-trace step. The import-permit experience for the stable oral tablet is procedurally straightforward; the operational complexity is at the prior-line-documentation gate.

Recent regulatory and access news for Rezurock

EMA (CHMP) issued a positive opinion for belumosudil in 2024 with subsequent European Commission marketing authorisation; the EPAR is at ema.europa.eu/medicines/Rezurock. The FDA Rezurock label is at accessdata.fda.gov/scripts/cder/daf. Sanofi continues post-marketing surveillance of belumosudil for organ-specific cGVHD subgroups. TITCK published Revision 14 of the Yurt Dışından İlaç Temini ve Kullanımı Kılavuzu on 29 August 2024; the İTS regulation per Anadolu Ajansı applies to belumosudil imports. No TITCK-specific bulletin on belumosudil over the last 12 months as of 2026-05-31.

Where Reserve Meds fits in Rezurock cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace TITCK, and we do not replace your dispensing pharmacy. For Rezurock specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Turkey, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Rezurock case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the TITCK application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Turkish specialty care concentrates at the Acibadem, American Hospital, and Memorial chains in Istanbul, with Hacettepe University Hospital in Ankara serving as the principal academic referral centre; the TITCK named-patient supply pathway is routed through the Turkish Pharmacists Association (TEB) foreign medicines channel.

Next step

If your Turkish physician has prescribed Rezurock and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Rezurock case Or message us on WhatsApp